The U.S. Food and Drug Administration (FDA) has accepted Sentynl Therapeutics Inc.’s New Drug Application (NDA) for CUTX-101 for filing and Priority review. CUTX-101 is a product candidate for the treatment of Menkes disease, a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. Recent estimates suggest a prevalence of 1 in 34,810 to as high as 1 in 8,664 live male births. Sentynl’s NDA is supported by positive topline clinical ef...